Department of Internal Medicine, Hematology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Hematology Clinic, Timisoara's Emergency City Hospital, 300723 Timisoara, Romania.
Medicina (Kaunas). 2021 Sep 27;57(10):1026. doi: 10.3390/medicina57101026.
Hodgkin lymphoma (HL) is characterized by the presence of malignant Reed Sternberg cells. Although the current curability rate in patients with HL has increased, up to 30% of those in the advanced stages and 5% to 10% of those in limited stages of the disease, relapse. According to the studies, the relapse risk in HL decreases after 2 years. The purpose of this study is to evaluate the relapse risk and event free survival (EFS) in patients with HL treated with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (ABVD), or treated with Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) regimens. In an observational, consecutive-case scenario, 71 patients (median age 32 years; range 16 to 80 years) diagnosed within a 4-year timeframe were enrolled; all patients were treated according to standards of care. The average follow-up duration was 26 months. The risk of relapse, in patients older than 40 years, decreased after 1 year, OR = 0.707 (95% CI 0.506 to 0.988), and 2 years, OR = 0.771 (95% CI 0.459 to 1.295), respectively. Patients in the advanced stages had a higher International Prognostic Score (IPS) (score ≥ 4). The overall survival at 2 years was 57.74% and the disease-specific survival at 2 years was 71.83%. Regardless, the chemotherapy regimen and the EFS time, advanced stage, high IPS and bulky disease were still associated with an increased relapse risk in patients with HL. The use of ABVD chemotherapy regimen followed by 2 years EFS was associated with a reduced relapse risk.
霍奇金淋巴瘤（HL）的特征是存在恶性里德-斯滕伯格细胞。尽管目前 HL 患者的治愈率有所提高，但是在晚期患者中高达 30%，在局限性疾病患者中高达 5%至 10%会复发。根据研究，HL 患者在 2 年后复发风险降低。本研究旨在评估接受多柔比星、博来霉素、长春碱和达卡巴嗪（ABVD）或博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、丙卡巴肼和泼尼松（BEACOPP）方案治疗的 HL 患者的复发风险和无事件生存（EFS）。在一项观察性、连续病例研究中，纳入了 71 名（中位年龄 32 岁；范围 16 至 80 岁）在 4 年内确诊的患者；所有患者均根据标准治疗方案进行治疗。平均随访时间为 26 个月。在年龄大于 40 岁的患者中，复发风险在 1 年后降低，OR=0.707（95%CI 0.506 至 0.988），2 年后降低，OR=0.771（95%CI 0.459 至 1.295）。晚期患者的国际预后评分（IPS）较高（评分≥4）。2 年总生存率为 57.74%，2 年疾病特异性生存率为 71.83%。无论化疗方案和 EFS 时间如何，晚期、高 IPS 和大肿块疾病仍然与 HL 患者的复发风险增加相关。ABVD 化疗方案后 2 年 EFS 的使用与降低复发风险相关。
